Long-term Adverse Effects After Bariatric Surgery on Oesophagus Epithelium (FUB-B)
Primary Purpose
Morbid Obesity
Status
Completed
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Gastroscopy
Sponsored by
About this trial
This is an interventional diagnostic trial for Morbid Obesity
Eligibility Criteria
Inclusion Criteria:
- Patients who received laparoscopic gastric bypass or laparoscopic sleeve gastrectomy ≥ 5 years ago as a primary bariatric procedure will be eligible for this study.
Exclusion Criteria:
- Patients who received laparoscopic gastric bypass or laparoscopic sleeve gastrectomy as a secondary bariatric procedure (e.g. after gastric banding),
- Patients who received a secondary bariatric operation after laparoscopic gastric bypass or laparoscopic sleeve gastrectomy( e.g. biliopancreatic diversion)
Sites / Locations
- St Claraspital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Gastric Bypass
Sleeve Gastrectomy
Arm Description
A gastroscopy will be carried out to document the presence of inflammation and metaplasia in patients after an average of 5 years after laparoscopic gastric bypass
A gastroscopy will be carried out to document the presence of inflammation and metaplasia in patients after an average of 5 years after laparoscopic sleeve gastrectomy
Outcomes
Primary Outcome Measures
Incidence of Barrett oesophagus after bariatric surgery
incidence of Barrett oesophagus will be compared to will be compared to reference for this age
Secondary Outcome Measures
Prevalence of dysphagia after bariatric surgery
Prevalence of dysphagia will be compared to will be compared to reference for this age
Prevalence of oesophageal motility disorders after bariatric surgery
Prevalence of oesophageal motility will be compared to will be compared to reference for this age
Full Information
NCT ID
NCT03410849
First Posted
January 2, 2018
Last Updated
November 2, 2020
Sponsor
University Hospital, Basel, Switzerland
1. Study Identification
Unique Protocol Identification Number
NCT03410849
Brief Title
Long-term Adverse Effects After Bariatric Surgery on Oesophagus Epithelium
Acronym
FUB-B
Official Title
Long-term Adverse Effects After Laparoscopic Sleeve Gastrectomy and Roux en Y Gastric Bypass (Part B)
Study Type
Interventional
2. Study Status
Record Verification Date
November 2020
Overall Recruitment Status
Completed
Study Start Date
February 1, 2018 (Actual)
Primary Completion Date
September 1, 2020 (Actual)
Study Completion Date
September 1, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Basel, Switzerland
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The goal of this trial is to examine long-term effects of laparoscopic gastric bypass (LRYGB) and sleeve gastrectomy (LSG) on oesophageal symptoms and disease, including the presence of Barrett oesophagus ≥ 5 years post-surgery.
Detailed Description
Bariatric surgery shows impressive results in terms of weight loss and resolution of comorbidities. Still, there are questions as to the frequency of long-term adverse effects: the prevalence and causes of post-operative swallowing disorders and reflux disease are uncertain. Recently, independent study groups described a high incidence of Barrett oesophagus post LSG. Additional research is urgently needed.
The goal of this trial is to examine long-term effects of laparoscopic gastric bypass (LRYGB) and sleeve gastrectomy (LSG) on oesophageal symptoms and disease, including the presence of Barrett oesophagus ≥ 5 years post-surgery.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Morbid Obesity
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
170 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Gastric Bypass
Arm Type
Active Comparator
Arm Description
A gastroscopy will be carried out to document the presence of inflammation and metaplasia in patients after an average of 5 years after laparoscopic gastric bypass
Arm Title
Sleeve Gastrectomy
Arm Type
Active Comparator
Arm Description
A gastroscopy will be carried out to document the presence of inflammation and metaplasia in patients after an average of 5 years after laparoscopic sleeve gastrectomy
Intervention Type
Diagnostic Test
Intervention Name(s)
Gastroscopy
Intervention Description
in both arms intervention 'gastroscopy' will be carried out
Primary Outcome Measure Information:
Title
Incidence of Barrett oesophagus after bariatric surgery
Description
incidence of Barrett oesophagus will be compared to will be compared to reference for this age
Time Frame
5-7 years after bariatric surgery
Secondary Outcome Measure Information:
Title
Prevalence of dysphagia after bariatric surgery
Description
Prevalence of dysphagia will be compared to will be compared to reference for this age
Time Frame
5-7 years after bariatric surgery
Title
Prevalence of oesophageal motility disorders after bariatric surgery
Description
Prevalence of oesophageal motility will be compared to will be compared to reference for this age
Time Frame
5-7 years after bariatric surgery
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients who received laparoscopic gastric bypass or laparoscopic sleeve gastrectomy ≥ 5 years ago as a primary bariatric procedure will be eligible for this study.
Exclusion Criteria:
Patients who received laparoscopic gastric bypass or laparoscopic sleeve gastrectomy as a secondary bariatric procedure (e.g. after gastric banding),
Patients who received a secondary bariatric operation after laparoscopic gastric bypass or laparoscopic sleeve gastrectomy( e.g. biliopancreatic diversion)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bettina Wölnerhanssen, MD
Organizational Affiliation
Clinical Research St Claraspital
Official's Role
Principal Investigator
Facility Information:
Facility Name
St Claraspital
City
Basel
ZIP/Postal Code
4016
Country
Switzerland
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Long-term Adverse Effects After Bariatric Surgery on Oesophagus Epithelium
We'll reach out to this number within 24 hrs